CINC424C2416: Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease (clinicaltrials.gov) - Aug 28, 2026 - P4 | N=36 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed • Acute Graft versus Host Disease • Graft versus Host Disease • Immunology
|